ContractClinical Trial Site Agreement • April 20th, 2020
CLINICAL TRIAL SITE AGREEMENT SMLOUVA O PROVÁDĚNÍ KLINICKÉHO HODNOCENÍ BETWEEN L’ASSISTANCE PUBLIQUE – HÔPITAUX DE PARIS, Publichealth institution with registered address at 3, Avenue Victoria, Paris 4ème, France represented by its General Director, xxxxxx, represented by xxxxxxx, Director of the Delegation for Clinical Research and Innovation, Carré Historique de l'Hôpital Saint-Louis, 1 av. Claude Vellefaux 75010 Paris, France in application of the directorial decree, Hereafter referred to as «AP-HP/Sponsor», of the one part, HAVING MANDATED The VALUE OUTCOMES s.r.o. company, having its registered office at Václavská 316/12, Prague 2, 120 00, maintained by the Municipial Court in Prague, Section C, File 94691, Represented by xxxxxxxx, Managing Director, duly authorized to sign and execute this agreement in the name and on behalf of APHP, Hereafter referred to as «CRO», AND The center University Hospital Brno,With the registered address at Jihlavská 20, 625 00 Brno, Czech RepublicID:
Clinical Trial Site AgreementClinical Trial Site Agreement • July 25th, 2018 • England and Wales
Full Title of Clinical Trial: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reachcomplete metabolic remission after first or second line salvage therapy Short Title and/or Acronym: ANIMATE EudraCT Number: 2017-002544-32 REC ref: 18/LO/0204 Sponsor: University College London Sponsor’s Project ID Number: UCL/15/0515 Funder: Bristol-Myers Squibb Pharmaceuticals Ltd(BMS protocol reference CA-209-445)
Clinical Trial Site AgreementClinical Trial Site Agreement • August 9th, 2020
This Agreement is entered into by and between [Name of Institution], with its principal location in [City], [State], hereinafter referred to as “Institution,” and [Sponsor Name], a [State] corporation with its principal place of business in [City], [State], hereinafter referred to as “Sponsor” (collectively, the “Parties”).
Clinical Trial Site AgreementClinical Trial Site Agreement • September 29th, 2014
This agreement (the “Agreement”: this agreement comprising its clauses, schedules and any appendices attached to it), pertaining to a clinical study defined hereinafter, is entered into by and between:
